Model of Ratanawichitrasin et al for Predicting the Likelihood of Residual Ductal Carcinoma in Situ (DCIS) Following Therapy

Purpose: To predict the likelihood of a woman treated for DCIS having residual disease using the model of Ratanwichitrasin et al.

Info MyLikes MyPaths

Evaluation

Are you evaluating a woman who has been treated for DCIS?

Yes

Does the patient have multifocal or extensive DCIS?

Yes

Does the DCIS show the comedo pattern?

Yes

Select an appropriate answer for each question

Reason for initial evaluation

Margin of previous margin

Results

Please fill out required fields.

Results Interpretation and Description References Next Steps

Data complete?

Evaluation appropriate?

Probability of having residual DCIS

MedicalAlgorithms.com APIs

Power Your Solutions with 5,000+ Automated Medical Analytics

Seamlessly integrate our API library of over 5,000 evidence-based medical analytics into your products and workflows. Our APIs help you:

Build custom, automated clinical workflows tailored to your organization's needs.
Enhance your clinical decision support with advanced, evidence-based analytics.
Streamline revenue cycle management by integrating clinical analytics into billing, coding, and compliance processes.
Support payment and pre-approval processes with automated, standardized medical criteria.
Embed proven medical algorithms directly into your systems and services for consistent, high-quality outcomes.

With MedicalAlgorithms.com APIs, you can accelerate innovation, improve efficiency, and deliver more accurate, data-driven care—without reinventing the wheel.

Explore Medal API

Caution: A qualified health practitioner should verify all results.
Keep patient data confidential and comply with all legal requirements.

Please visit our website Medicalalgorithms.com for Description and Interpretation and further algorithms you may want to consider in the next steps of your evaluation. All information should be verified by a qualified health professional, and all use is subject to Medicalalgorithms.com Terms and Conditions. © Copyright Medicalalgorithms.com Limited

Interpretation and Description

References

Next Steps in Evaluation

Diagnosis

Risk Factors
Clinical Diagnosis, Including Family History For Genetics
- Pedigree Assessment Tool (PAT) of Hoskins et al for Identifying a Woman at High Risk for Hereditary Breast Cancer
Laboratory Tests
- Elston's Modification for the Criteria of Bloom and Richardson in the Histologic Grading of Infiltrating Ductal Carcinoma
- Allred Score for Reporting Estrogen Receptor Status by Immunohistochemistry for a Woman with Breast Cancer
Other Testing
- Predicting Local Recurrence Risk Following Breast Conserving Therapy for Ductal Carcinoma in Situ (DCIS)
Severity, Prognosis, Stage

Therapy

Selection

Monitoring

Response To Therapy
Disease Progression
- Scoring Breast Cosmesis Following Therapy
- Clinical-Pathologic Scoring System (CPS and CPS+EG) of Jeruss et al for Evaluating a Woman with Breast Cancer After Neoadjuvant Therapy

Patient Concerns

Quality Of Life
- Scoring Breast Cosmesis Following Therapy
Psychological Response
- Scoring Breast Cosmesis Following Therapy

Specialty

Hematology Oncology
Surgery, general
Obstetrics & Gynecology

Objective

risk factors
severity
prognosis
stage
response to therapy

ICD-10

C50 - Malignant neoplasm of breast
D05 - Carcinoma in situ of breast

Info

Purpose: To predict the likelihood of a woman treated for DCIS having residual disease using the model of Ratanwichitrasin et al.

Specialty: Hematology Oncology, Surgery, general, Obstetrics & Gynecology

Objective: risk factors, severity, prognosis, stage, response to therapy

ICD-10: C50, D05,

Save Data

Identifier

Enter 1 to 5 characters as ID

Email

Your registered email

Other

Email to

Please separate multiple email IDs with comma (,)

Consult Report

Identifier

Enter 1 to 5 characters as ID

Add to MyPath

Select path

New path